MARK GILBERT was named chief of the Neuro-Oncology Branch at the NIH, within the Center for Cancer Research of NCI.
ASTRAZENECA, Pharmacyclics Inc. and Janssen Research & Development LLC entered into a clinical trial collaboration to evaluate the efficacy and safety of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Imbruvica (ibrutinib).
DANA-FARBER CANCER INSTITUTE and Astellas Pharma Inc. announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.
THE HARRINGTON DISCOVERY INSTITUTE at University Hospitals and the University of Oxford formed an affiliation focused on drug discovery projects.
ANTJE HOERING was named CEO of Cancer Research and Biostatistics, effective Jan. 1, 2015.
ROSEMARIE HENSON will join the American Cancer Society as senior vice president for prevention and early detection, effective January 2015.
MICHAEL BISHOP will receive the Daniel Nathans Memorial Award for his contributions to biomedical research from the Van Andel Research Institute.
SUSAN O'BRIEN will join UC Irvine Health as associate director for clinical science for the Chao Family Comprehensive Cancer Center and medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research. Her appointment is effective Jan. 1, 2015.
THE COMMUNITY ONCOLOGY ALLIANCE documented an 82 percent increase in cancer clinic closings and a 143 percent increase in consolidation into hospitals in a new report since its first in 2010, which reported on activity from 2008 to 2010.
THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY formed a clinical affairs department focused on to providing services, education, and resources to support oncology practices.
